Company Overview and News

 
Another Freaky Friday

2018-04-09 seekingalpha
The tale of the tape seldom lies, well at least today’s virtual one, which has been swinging widely on the seismic shifts in trade war sentiment. Also, Friday was no exception when calm gave way to horror as panic-stricken investors ran for the exits. Friday’s soft March US jobs and bellicose trade war rhetoric were the main ingredients amongst a toxic brew of factors that sent US stock markets plunging.
Upvote Downvote

 
New board brings new hopes for SriLankan

2018-04-06 dailymirror.lk
From left: National Public Private Partnership Agency Chairman Thilan Wijesinghe, SriLankan Directors Susantha Katugampala, Mano Tittawella, Ranjit Fernando (Chairman), Air Marshal Kapila Jayampathi and Dr.Roshan Perara Pic by Samantha Perera
Upvote Downvote

3
Product Tanker Market Supply & Demand Update

2018-04-04 seekingalpha
Note: This is a short summary of an article originally published March 9th on Value Investor's Edge. For access to the full article which contains further information on trade flow shifts, new refinery capacity, arbitrage opportunities, and global product stockpiles please click here.
Upvote Downvote

 
So What's Going On With Auto Sales?

2018-04-04 seekingalpha
With US auto sales facing some stiff headwinds, timely data is no longer wanted, said GM Monday night, when it announced that it would no longer report new-vehicle unit sales in the US on a monthly basis to make it "easier" for us. This has been bread-and-butter data of the auto industry. But forget it. Now it's like so TMI. Sez GM:
Upvote Downvote

 
Tech rout? China just got busy puffing up its own boom

2018-04-03 livemint
Hong Kong:Just as US technology shares are losing air, China’s planning to engineer its own boom.
Upvote Downvote

 
Do Your Target-Date Funds Measure Up To Rising Rates?

2018-03-31 valuewalk
Rising US interest rates could pose a challenge for target-date funds (TDFs) that concentrate on “core” US fixed-income exposure. Diversifying across a broad range of bond markets and strategies can create a cushion in a rising-rate environment.
Upvote Downvote

 
Complicatedly Confounding Currency Moves

2018-03-28 seekingalpha
One of the best Easter egg hunts shaping up is trying to find the elusive US dollar narrative. Outside of the dollar-yen, the market was distinctly bearish to open the week, but then the likely combination of month-end/quarter-end and Easter holidays whetted into context and the dollar tore through G-10 currency markets like a runaway train overnight.
Upvote Downvote

 
Tariffs, Trade War Concerns Help Spark Equity Market Sell-Off

2018-03-28 blog.invesco.us
Weekly Market Compass: With multiple factors contributing to market volatility, consumer sentiment and economic data could prove telling
Upvote Downvote

 
Tech stocks pull market sharply lower, erasing early gains

2018-03-27 sfgate
A steep, late-afternoon sell-off in technology companies pulled stocks sharply lower Tuesday, knocking 344 points off the Dow Jones industrial average.
Upvote Downvote

 
Netflix job pays $549K, more than double the usual market rate

2018-03-27 nzherald.co.nz
Netflix has turned heads in Hollywood by spending billions of dollars to lure filmmakers and viewers from rival TV networks. But it's also frustrated competitors in a less-public way: by poaching talent and driving up pay.
Upvote Downvote

 
As trade war simmers, currency whales make their move

2018-03-27 nzherald.co.nz
For the first time in a decade, the world's central banks are looking beyond the US dollar to build their currency reserves.
Upvote Downvote

 
Biggest currency whales make their move amid trade war tensions

2018-03-27 themalaymailonline
The German Central Bank (Bundesbank) presents the new €50 banknote at its headquarters in Frankfurt, March 16, 2017. — Reuters picNEW YORK, March 27 — For the first time in a decade, the world’s central banks are looking beyond the US dollar to build their currency reserves.
Upvote Downvote

 
Grab vanquishes Uber with local strategy, billions from SoftBank

2018-03-26 themalaymailonline
Grab co-founder and chief executive officer Anthony Tan. — File picSINGAPORE, March 27 — As Uber Technologies Inc looked to conquer ride-sharing around the world, Grab was focused on serving the 620 million people that share its home in South-east Asia.
Upvote Downvote

 
Oil prices dip on profit taking after last week’s rally

2018-03-26 themalaymailonline
An oil well is pictured at sunrise in the Bakken oil fields near Sidney, Montana in this November 2014 handout photo. — Reuters picNEW YORK, March 27 — Crude oil futures slipped yesterday as investors cashed in some profits from last week's rally but concerns about Saudi-Iran tensions kept losses in check.
Upvote Downvote

 
Oil prices fall on profit taking after big weekly gain

2018-03-26 cnbc
Crude oil futures slipped on Monday as investors cashed in some profits from last week's strong rise, but concerns about Saudi-Iran tensions kept losses in check.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...